Related Experiment Videos
Management of bone metastases
1Yorkshire Cancer Research Department of Clinical Oncology, Cancer Research Center, Weston Park Hospital, Sheffield, England. r.e.coleman@sheffield.ac.uk
The Oncologist
|December 8, 2000
Summary
Metastatic bone disease involves tumor and bone cell interactions, disrupting bone metabolism. Bisphosphonates offer a key treatment strategy to reduce symptoms and complications in cancer patients.
Area of Science:
- Oncology
- Bone Biology
- Pharmacology
Background:
- Metastatic bone disease arises from complex tumor-bone cell interactions.
- Increased osteoclast activity is a hallmark, driving skeletal complications in cancers like myeloma, breast, and prostate.
- Skeletal complications significantly impair patient quality of life.
Purpose of the Study:
- To review the role of bisphosphonates in managing metastatic bone disease.
- To highlight emerging molecular therapies targeting cancer-induced bone disease.
- To discuss ongoing research in optimizing bisphosphonate therapy and exploring their adjuvant potential.
Main Methods:
- Review of current treatment strategies for metastatic bone disease.
- Discussion of bisphosphonates as a therapeutic intervention.
- Overview of novel molecular agents and ongoing clinical trials.
Main Results:
- Bisphosphonates effectively reduce symptoms and complications of bone involvement.
- New targeted molecules like osteoprotegerin show promise in clinical trials.
- Research is refining bisphosphonate use for metastatic bone disease and cancer-related osteoporosis.
Conclusions:
- Bisphosphonates are crucial in managing metastatic bone disease, improving patient outcomes.
- Targeted therapies based on cellular signaling are advancing cancer-induced bone disease treatment.
- Further research into bisphosphonates may reveal their utility in preventing bone metastases.